Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial
Oncology Research and Treatment · 29.05.2026 · 1-8
DOI: 10.1159/000552693 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Oncology Research and Treatment, online erschienen am 29.05.2026. Verfasst von Gertraud Stocker und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine (Oncology, Gastroenterology, Hepatology and Pulmonology) and University Cancer Center Leipzig, Cancer Center Central Germany (…. Hauptthemen laut MEDLINE: Adenocarcinoma, Antineoplastic Combined Chemotherapy Protocols, Esophageal Neoplasms, Stomach Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Despite advances in the multimodal treatment of resectable esophagogastric adenocarcinoma (EGA), relapse rates remain high. No human epidermal growth factor receptor 2 (HER2)-targeted treatment is yet established in the perioperative setting. While trastuzumab deruxtecan (T-DXd) has compelling efficacy and is now a well-established drug in the treatment of advanced HER2-positive EGA, safety and efficacy data from the perioperative setting are still lacking.
Methods
NeoART is a phase Ib/II platform trial evaluating the safety and efficacy of neoadjuvant T-DXd-containing combination regimens for patients with HER2-positive EGA. We report about the safety, feasibility, and preliminary antitumor activity from the safety run-in cohort of the NeoART trial in which patients with locally advanced resectable EGA received three cycles of preoperative T-DXd (5.4 mg/kg, Q3W) combined with 5-fluorouracil (5-FU; 2,600 mg/m2 24 h, Q2W) and folinic acid (FA; 200 mg/m2, Q2W).
Results
In the preplanned safety analysis of the first 6 patients recruited to NeoART, no serious adverse events (SAEs) or dose-limiting toxicities (DLTs) were reported during neoadjuvant treatment. Relevant treatment-related adverse events of grades 1–3 were diarrhea, mucositis, and nausea, but none fulfilled the criteria of DLTs. No relevant hematologic toxicity was observed. Five of six patients underwent curative-intent oncologic resection. In one patient, peritoneal carcinomatosis was detected at the time of surgery; therefore, the tumor was not resected. Two patients experienced grade 3 postoperative complications according to Clavien-Dindo classification, including one anastomotic leakage which was classified as an SAE. R0 resection was accomplished in four out of five resected patients. Histopathological complete remission (pCR; ypT0 N0) was observed in two patients.
Conclusions
Neoadjuvant treatment with T-DXd plus 5-FU/FA was found to be well tolerated and showed preliminary signs of activity during the safety run-in period of the NeoART study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine (Oncology, Gastroenterology, Hepatology and Pulmonology) and University Cancer Center Leipzig, Cancer Center Central Germany (CCCG), University of Leipzig Medical Center, Leipzig, Germany, gertrau…
- Department of Medicine III (Hematology, Oncology and Cell Therapy), Klinikum Chemnitz, Chemnitz, Germany.
- Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
- Frankfurt Institute of Clinical Cancer Research (IKF) and University Cancer Center UCT Frankfurt, Frankfurt am Main, Germany.
- Department of Medicine II (Hematology and Oncology), Cancer Center Central Germany (CCCG), Universitätsklinikum Jena, Jena, Germany.
- Department of Medicine III, TUM University Hospital Rechts der Isar, Munich, Germany.
Zitieren
APA
Stocker, G., Chater, J., Ettrich, T. J., Goetze, T. O., Lindig, R. U., Lorenzen, S., Stein, A., Junge, S., Pauligk, C., Al-Batran, S. E., & Lordick, F. (2026). Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial. Oncology Research and Treatment, 1-8. https://doi.org/10.1159/000552693
Vancouver
Stocker G, Chater J, Ettrich TJ, Goetze TO, Lindig RU, Lorenzen S, et al. Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial. Oncology Research and Treatment. 2026:1-8. doi:10.1159/000552693
BibTeX
@article{Stocker2026,
author = {Stocker, Gertraud and Chater, Jack and Ettrich, Thomas J and Goetze, Thorsten O and Lindig, Reinhard U and Lorenzen, Sylvie and Stein, Alexander and Junge, Sabine and Pauligk, Claudia and Al-Batran, Salah-Eddin and Lordick, Florian},
title = {Safety and Preliminary Activity of Neoadjuvant Trastuzumab Deruxtecan plus 5-Fluorouracil and Folinic Acid for HER2-Positive, Resectable Esophagogastric Adenocarcinoma: Results from the Safety Run-In Cohort of the Phase Ib/II UCCL-AIO-STO0124-IKF072 NeoART Trial},
journal = {Oncology Research and Treatment},
year = {2026},
pages = {1--8},
doi = {10.1159/000552693}
}
EUVIMED